A carregar...
Efficacy of eplerenone in the management of mineralocorticoid excess in men with metastatic castration resistant prostate cancer treated with abiraterone without prednisone
Prednisone is typically co-administered with abiraterone in treatment of castrate resistant prostate cancer to prevent toxicities of secondary mineralocorticoid excess. However, many patients do not desire or cannot tolerate chronic glucocorticoid therapy. In this retrospective study, we report that...
Na minha lista:
| Publicado no: | Clin Genitourin Cancer |
|---|---|
| Main Authors: | , , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5501307/ https://ncbi.nlm.nih.gov/pubmed/28131750 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.clgc.2016.12.008 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|